Drug Profile
Research programme: drug discovery - ChemDiv/Kaken
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator ChemDiv; Kaken Pharmaceutical
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Undefined in USA
- 26 Mar 2009 Preclinical development is ongoing in USA
- 26 Feb 2007 Preclinical trials in Undefined in USA (unspecified route)